Understanding Your Breast Cancer Patient’s True Risk of Recurrence
MammaPrint analyzes the 70 critical genes identified in breast cancer metastasis to determine a woman’s true risk of recurrence. MammaPrint provides a definitive result of Low Risk or High Risk of metastasis. With MammaPrint, there are no intermediate results, so there is no uncertainty about your patient’s individual risk and her treatment needs.
Many surgeons and oncologists rely on MammaPrint with other clinical criteria to assist in their therapeutic decision making. When combined with traditional risk factors, if a breast cancer patient is Low Risk by MammaPrint hormonal therapy (e.g. Tamoxifen) alone may be sufficient to further reduce her recurrence risk. Conversely, if a breast cancer patient is High Risk by MammaPrint and has additional risk factors, she may benefit from more aggressive treatment including chemotherapy .
Using MammaPrint in conjunction with other clinical criteria and pathology test results enables treating physicians to make therapeutic decisions with confidence. MammaPrint test results enable individually tailored treatment regimens for early stage breast cancer patients.
MammaPrint provides a dichotomous (binary) test result: the patient is either at Low Risk or High Risk of developing distant metastases. There are no intermediate results.
Low Risk Result:
A “Low Risk” MammaPrint result means that a patient has a 10% chance that her cancer will recur within 10 years without any additional adjuvant treatment, either hormonal therapy or chemotherapy.
High Risk Result:
A “High Risk” MammaPrint result means that a patient has a 29% chance that her cancer will recur within 10 years without any additional adjuvant treatment, either hormonal therapy or chemotherapy.
Agendia offers a variety of reporting options to meet your needs. Results are available via email, FedEx and soon online intranet reporting. If you have any questions about these options, please feel free to contact us at Genome Investigation Ltd or Agendia’s Customer Care Team.
1) FDA Label – USFDA Clearance; http://www.accessdata.fda.gov website.
2) Buyse M, Loi S, van ’t Veer L, et al., J Natl Cancer Inst 2006; 98(17):1183-1192